Excelsior Sciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Excelsior Sciences is a private, pre-revenue biotech founded in 2018 that is developing an automated, AI-integrated platform for small molecule discovery and manufacturing. Its core innovation is 'Blocc Chemistry,' which uses standardized, machine-ready building blocks to enable rapid, iterative, closed-loop synthesis and testing. Backed by $95M in Series A funding from top-tier investors, the company is building a proprietary therapeutic pipeline while also pursuing collaborations to transform how molecules are made across multiple industries.

Small Molecules

Technology Platform

Blocc Chemistry: A machine-friendly, modular platform using standardized building blocks (smart bloccs) for automated, iterative C-C bond formation, integrated with AI-driven closed-loop learning and discovery cycles.

Opportunities

The platform addresses massive markets in pharmaceutical, materials, and agrochemical discovery by dramatically accelerating and derisking the molecule creation process.

The push for supply chain resilience and reshoring of manufacturing provides a powerful secondary strategic tailwind for its automated production capabilities.

Risk Factors

Key risks include the unproven scalability and versatility of the core Blocc Chemistry approach, the challenge of convincing large industries to adopt a new external platform, and intense competition from both large pharma and other techbio startups in the AI-driven discovery space.

Competitive Landscape

Excelsior competes in the emerging field of AI-integrated drug discovery. It differentiates with a proprietary focus on machine-ready chemistry and automated physical synthesis, unlike pure AI software companies. Competitors include other techbio startups (e.g., Genesis Therapeutics, Insilico Medicine) and internal efforts at large pharmaceutical firms.

More companies in Small Molecule Drugs →More companies in United States →